vs
IMPINJ INC（PI）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是IMPINJ INC的1.9倍（$140.6M vs $74.3M），VERACYTE, INC.净利率更高（29.3% vs 11.2%，领先18.1%），VERACYTE, INC.同比增速更快（18.5% vs -0.0%），VERACYTE, INC.自由现金流更多（$48.8M vs $2.2M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -14.9%）
Impinj Inc.是一家美国射频识别（RFID）设备及软件提供商，成立于2000年，总部位于华盛顿州西雅图，源自加州理工学院Carver Mead与Chris Diorio的研究成果。公司主营EPC Class 1 Gen 2无源超高频RFID芯片、读写器、读写器芯片、天线，以及芯片编码、业务数据采集相关的软件应用，为各行业RFID应用提供全链路产品支持。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PI vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.9倍
$74.3M
营收增速更快
VCYT
高出18.6%
-0.0%
净利率更高
VCYT
高出18.1%
11.2%
自由现金流更多
VCYT
多$46.6M
$2.2M
两年增速更快
VCYT
近两年复合增速
-14.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $74.3M | $140.6M |
| 净利润 | $8.3M | $41.1M |
| 毛利率 | 49.1% | 72.5% |
| 营业利润率 | 30.5% | 26.4% |
| 净利率 | 11.2% | 29.3% |
| 营收同比 | -0.0% | 18.5% |
| 净利润同比 | — | 704.8% |
| 每股收益（稀释后） | $0.14 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PIVCYT
| Q1 26 | $74.3M | — | ||
| Q4 25 | $92.8M | $140.6M | ||
| Q3 25 | $96.1M | $131.9M | ||
| Q2 25 | $97.9M | $130.2M | ||
| Q1 25 | $74.3M | $114.5M | ||
| Q4 24 | $91.6M | $118.6M | ||
| Q3 24 | $95.2M | $115.9M | ||
| Q2 24 | $102.5M | $114.4M |
净利润PIVCYT
| Q1 26 | $8.3M | — | ||
| Q4 25 | $-1.1M | $41.1M | ||
| Q3 25 | $-12.8M | $19.1M | ||
| Q2 25 | $11.6M | $-980.0K | ||
| Q1 25 | $-8.5M | $7.0M | ||
| Q4 24 | $-2.7M | $5.1M | ||
| Q3 24 | $221.0K | $15.2M | ||
| Q2 24 | $10.0M | $5.7M |
毛利率PIVCYT
| Q1 26 | 49.1% | — | ||
| Q4 25 | 51.8% | 72.5% | ||
| Q3 25 | 50.3% | 69.2% | ||
| Q2 25 | 57.8% | 69.0% | ||
| Q1 25 | 49.4% | 69.5% | ||
| Q4 24 | 50.5% | 66.4% | ||
| Q3 24 | 50.0% | 68.2% | ||
| Q2 24 | 56.1% | 68.1% |
营业利润率PIVCYT
| Q1 26 | 30.5% | — | ||
| Q4 25 | -2.9% | 26.4% | ||
| Q3 25 | 0.7% | 17.4% | ||
| Q2 25 | 11.1% | -4.0% | ||
| Q1 25 | -12.9% | 2.5% | ||
| Q4 24 | -3.9% | 3.5% | ||
| Q3 24 | -0.8% | 10.4% | ||
| Q2 24 | 8.8% | 4.0% |
净利率PIVCYT
| Q1 26 | 11.2% | — | ||
| Q4 25 | -1.2% | 29.3% | ||
| Q3 25 | -13.3% | 14.5% | ||
| Q2 25 | 11.8% | -0.8% | ||
| Q1 25 | -11.4% | 6.2% | ||
| Q4 24 | -2.9% | 4.3% | ||
| Q3 24 | 0.2% | 13.1% | ||
| Q2 24 | 9.7% | 5.0% |
每股收益（稀释后）PIVCYT
| Q1 26 | $0.14 | — | ||
| Q4 25 | $-0.02 | $0.50 | ||
| Q3 25 | $-0.44 | $0.24 | ||
| Q2 25 | $0.39 | $-0.01 | ||
| Q1 25 | $-0.30 | $0.09 | ||
| Q4 24 | $-0.06 | $0.07 | ||
| Q3 24 | $0.01 | $0.19 | ||
| Q2 24 | $0.34 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $131.8M | $362.6M |
| 总债务越低越好 | $241.5M | — |
| 股东权益账面价值 | — | $1.3B |
| 总资产 | $502.5M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PIVCYT
| Q1 26 | $131.8M | — | ||
| Q4 25 | $175.3M | $362.6M | ||
| Q3 25 | $190.1M | $315.6M | ||
| Q2 25 | $193.2M | $219.5M | ||
| Q1 25 | $147.9M | $186.1M | ||
| Q4 24 | $164.7M | $239.1M | ||
| Q3 24 | $170.3M | $274.1M | ||
| Q2 24 | $220.2M | $235.9M |
总债务PIVCYT
| Q1 26 | $241.5M | — | ||
| Q4 25 | $280.9M | — | ||
| Q3 25 | $280.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $283.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PIVCYT
| Q1 26 | — | — | ||
| Q4 25 | $209.2M | $1.3B | ||
| Q3 25 | $195.0M | $1.3B | ||
| Q2 25 | $187.7M | $1.2B | ||
| Q1 25 | $160.6M | $1.2B | ||
| Q4 24 | $149.9M | $1.2B | ||
| Q3 24 | $136.1M | $1.2B | ||
| Q2 24 | $117.0M | $1.1B |
总资产PIVCYT
| Q1 26 | $502.5M | — | ||
| Q4 25 | $545.2M | $1.4B | ||
| Q3 25 | $516.5M | $1.4B | ||
| Q2 25 | $508.8M | $1.3B | ||
| Q1 25 | $479.8M | $1.3B | ||
| Q4 24 | $489.1M | $1.3B | ||
| Q3 24 | $476.4M | $1.3B | ||
| Q2 24 | $446.1M | $1.2B |
负债/权益比PIVCYT
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.89× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $2.2M | $48.8M |
| 自由现金流率自由现金流/营收 | 3.0% | 34.7% |
| 资本支出强度资本支出/营收 | — | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $61.1M | $126.6M |
8季度趋势，按日历期对齐
经营现金流PIVCYT
| Q1 26 | — | — | ||
| Q4 25 | $15.1M | $52.6M | ||
| Q3 25 | $20.9M | $44.8M | ||
| Q2 25 | $33.9M | $33.6M | ||
| Q1 25 | $-11.1M | $5.4M | ||
| Q4 24 | $12.6M | $24.5M | ||
| Q3 24 | $10.1M | $30.0M | ||
| Q2 24 | $45.5M | $29.6M |
自由现金流PIVCYT
| Q1 26 | $2.2M | — | ||
| Q4 25 | $13.6M | $48.8M | ||
| Q3 25 | $18.0M | $42.0M | ||
| Q2 25 | $27.3M | $32.3M | ||
| Q1 25 | $-13.0M | $3.5M | ||
| Q4 24 | $8.5M | $20.4M | ||
| Q3 24 | $4.7M | $27.7M | ||
| Q2 24 | $44.1M | $26.8M |
自由现金流率PIVCYT
| Q1 26 | 3.0% | — | ||
| Q4 25 | 14.7% | 34.7% | ||
| Q3 25 | 18.7% | 31.8% | ||
| Q2 25 | 27.9% | 24.8% | ||
| Q1 25 | -17.5% | 3.1% | ||
| Q4 24 | 9.3% | 17.2% | ||
| Q3 24 | 4.9% | 23.9% | ||
| Q2 24 | 43.0% | 23.4% |
资本支出强度PIVCYT
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 2.7% | ||
| Q3 25 | 3.1% | 2.1% | ||
| Q2 25 | 6.7% | 1.0% | ||
| Q1 25 | 2.5% | 1.6% | ||
| Q4 24 | 4.5% | 3.5% | ||
| Q3 24 | 5.7% | 1.9% | ||
| Q2 24 | 1.3% | 2.4% |
现金转化率PIVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | 2.93× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 45.56× | 1.98× | ||
| Q2 24 | 4.56× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PI
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
